Nasus Pharma Ltd. (NSRX)
NYSEAMERICAN: NSRX · Real-Time Price · USD
2.700
-0.050 (-1.82%)
May 19, 2026, 4:00 PM EDT - Market closed

Nasus Pharma Stock Forecast

Stock Price Forecast

According to 2 analysts polled by S&P Global, Nasus Pharma stock has a consensus rating of "Buy" and an average price target of $20. The average 1-year stock price forecast is 640.74% higher than the current stock price, while the lowest is $18 (+566.67%) and the highest is $22 (+714.81%).

Price Target: $20 (+640.74%)
Analyst Consensus: Buy
TargetLowAverageMedianHigh
Price$18$20$20$22
Change+566.67%+640.74%+640.74%+714.81%
* Price targets were last updated on Mar 26, 2026.

Analyst Ratings

The average analyst rating for Nasus Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

RatingFeb '26Mar '26Apr '26May '26
Strong Buy1111
Buy1222
Hold0000
Sell0000
Strong Sell0000
Total2333

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Citizens
Citizens
Buy
Maintains
$19$18
BuyMaintains$19$18+566.67%Mar 26, 2026
Citizens
Citizens
Buy
Initiates
$19
BuyInitiates$19+603.70%Dec 18, 2025
Laidlaw & Co.
Laidlaw & Co.
Strong Buy
Initiates
$22
Strong BuyInitiates$22+714.81%Sep 29, 2025

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.65
from -0.73
EPS Next Year
-1.49
from -1.65
Fiscal YearFY 2022FY 2023FY 2024FY 2025FY 2026FY 2027FY 2028
Period EndingDec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026Dec 31, 2027Dec 31, 2028
Revenue
------7.29M
Revenue Growth
-------
EPS
-0.25-0.20-0.22-0.73-1.65-1.49-1.38
EPS Growth
-------
Forward PE
-------
No. Analysts
----443
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue202620272028
Highn/an/a
Avgn/an/a
Lown/an/a

Revenue Growth

Revenue Growth202620272028
High--
Avg--
Low--

EPS Forecast

EPS202620272028
High-1.07-1.19
Avg-1.65-1.49
Low-2.18-1.75

EPS Growth

EPS Growth202620272028
High--
Avg--
Low--
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.